Growing tumors induce a local STING dependent Type I IFN response in dendritic cells

International Journal of Cancer

Volumn 139, Issue 6, 2016, Pages 1350-1357

  Andzinski, Lisa ^a   Spanier, Julia ^b   Kasnitz, Nadine ^a   Kröger, Andrea ^a,c   Jin, Lei ^d   Brinkmann, Melanie M ^a,e   Kalinke, Ulrich ^b   Weiss, Siegfried ^a,e   Jablonska, Jadwiga ^a,f   Lienenklaus, Stefan ^a,b,e  

^a HELMHOLTZ CENTRE FOR INFECTION RESEARCH   (Germany)

^b INSTITUTE OF INFECTION IMMUNOLOGY   (Germany)

^c OTTO VON GUERICKE UNIVERSITY   (Germany)

^d ALBANY MEDICAL COLLEGE   (United States)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; INTERFERON; INTERFERON REGULATORY FACTOR 3; INTERFERON REGULATORY FACTOR 5; PROTEIN STING; RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CANCER INFILTRATION; CANCER THERAPY; COLON CARCINOMA; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DENDRITIC CELL; FEMALE; FIBROSARCOMA; FLUORESCENCE ACTIVATED CELL SORTING; IMMUNOSURVEILLANCE; LUNG CARCINOMA; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN INDUCTION; SIGNAL TRANSDUCTION; SOLID TUMOR;

EID: 84977558573     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30159     Document Type: Article

References (50)

1. Isaacs A, Lindenmann J. Virus interference. I. The interferon. By A. Isaacs and J. Lindenmann, 1957. J Interferon Res 1987;7:429–38.
2. Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004;202:8–32.
3. Gonzalez-Navajas JM, Lee J, David M, et al. Immunomodulatory functions of type I interferons. Nat Rev Immunol 2012;12:125–35.
4. Gough DJ, Messina NL, Clarke CJP, et al. Constitutive type I interferon modulates homeostatic balance through tonic signaling. Immunity 2012;36:166–74.
5. Honda K, Mizutani T, Taniguchi T. Negative regulation of IFN-alpha/beta signaling by IFN regulatory factor 2 for homeostatic development of dendritic cells. Proc Natl Acad Sci USA 2004;101:2416–21.
6. Deonarain R, Verma A, Porter AC, et al. Critical roles for IFN-beta in lymphoid development, myelopoiesis, and tumor development: links to tumor necrosis factor alpha. Proc Natl Acad Sci USA 2003;100:13453–8.
7. Wang BX, Rahbar R, Fish EN. Interferon: current status and future prospects in cancer therapy. J Interf Cytokine Res 2011;31:545–52.
8. Jablonska J, Leschner S, Westphal K, et al. Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model. J Clin Invest 2010;120:1151–64.
9. Jablonska J, Wu C-F, Andzinski L, Leschner S, Weiss S. CXCR2-mediated tumor-associated neutrophil recruitment is regulated by IFN-β. Int J Cancer 2013;134 (6):1346–58.
10. Andzinski L, Wu C-F, Lienenklaus S, et al. Delayed apoptosis of tumor associated neutrophils in the absence of endogenous IFN-β. Int J Cancer 2015;136:572–83.
11. Wu C-F, Andzinski L, Kasnitz N, et al. The lack of type I interferon induces neutrophil-mediated pre-metastatic niche formation in the mouse lung. Int J Cancer 2015;137:837–47.
12. Lienenklaus S, Cornitescu M, Zietara N, et al. Novel reporter mouse reveals constitutive and inflammatory expression of IFN-beta in vivo. J Immunol 2009;183:3229–36.
13. Häcker H, Redecke V, Blagoev B, et al. Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature 2006;439:204–7.
14. Lazear HM, Lancaster A, Wilkins C, et al. IRF-3, IRF-5, and IRF-7 coordinately regulate the type I IFN response in myeloid dendritic cells downstream of MAVS signaling. PLoS Pathog 2013;9:e1003118
15. Mancl ME, Hu G, Sangster-Guity N, et al. Two discrete promoters regulate the alternatively spliced human interferon regulatory factor-5 isoforms. Multiple isoforms with distinct cell type-specific expression, localization, regulation, and function. J Biol Chem 2005;280:21078–90.
16. Solodova E, Jablonska J, Weiss S, et al. Production of IFN-β during Listeria monocytogenes infection is restricted to monocyte/macrophage lineage. PLoS One 2011;6:e18543
17. Spanier J, Lienenklaus S, Paijo J, et al. Concomitant TLR/RLH signaling of radioresistant and radiosensitive cells is essential for protection against vesicular stomatitis virus infection. J Immunol 2014;193:3045–54.
18. Jin L, Xu L-G, Yang IV, et al. Identification and characterization of a loss-of-function human MPYS variant. Genes Immun 2011;12:263–9.
19. Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat Rev Immunol 2014;14:36–49.
20. Fuertes MB, Kacha AK, Kline J, et al. Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8alpha+ dendritic cells. J Exp Med 2011;208:2005–16.
21. Noppert SJ, Fitzgerald KA, Hertzog PJ. The role of type I interferons in TLR responses. Immunol Cell Biol 2007;85:446–57.
22. Loo Y-M, Gale M. Immune signaling by RIG-I-like receptors. Immunity 2011;34:680–92.
23. Paludan SR, Bowie AG. Immune sensing of DNA. Immunity 2013;38:870–80.
24. Cai X, Chiu Y-H, Chen ZJ. The cGAS-cGAMP-STING pathway of cytosolic DNA sensing and signaling. Mol Cell 2014;54:289–96.
25. Barnes B, Lubyova B, Pitha PM. On the role of IRF in host defense. J Interferon Cytokine Res 2002;22:59–71.
26. Taniguchi T, Takaoka A. A weak signal for strong responses: interferon-alpha/beta revisited. Nat Rev Mol Cell Biol 2001;2:378–86.
27. Gresser I, Maury C, Bandu MT, et al. Importance of interferon alpha in the resistance of allogeneic C57B1/6 mice to the multiplication of Friend erythroleukemia cells in the liver. Int J Cancer 1990;45:364–71.
28. Picaud S, Bardot B, De Maeyer E, et al. Enhanced tumor development in mice lacking a functional type I interferon receptor. J Interferon Cytokine Res 2002;22:457–62.
29. Maguire JE, Gresser I, Williams AH, et al. Modulation of expression of MHC antigens in the kidneys of mice by murine interferon-alpha/beta. Transplantation 1990;49:130–4.
30. Takaoka A, Hayakawa S, Yanai H, et al. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 2003;424:516–23.
31. Dunn GP, Bruce AT, Sheehan KCF, et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol 2005;6:722–9.
32. Mizutani T, Neugebauer N, Putz EM, et al. Conditional IFNAR1 ablation reveals distinct requirements of Type I IFN signaling for NK cell maturation and tumor surveillance. Oncoimmunology 2012;1:1027–37.
33. Bekisz J, Sato Y, Johnson C, et al. Immunomodulatory effects of interferons in malignancies. J Interferon Cytokine Res 2013;33:154–61.
34. Harlin H, Meng Y, Peterson AC, et al. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 2009;69:3077–85.
35. Bald T, Landsberg J, Lopez-Ramos D, et al. Immune-cell poor melanomas benefit from PD-1 blockade after targeted type I IFN activation. Cancer Discov 2014;4:674–87.
36. Le Bon A, Schiavoni G, D'Agostino G, et al. Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001;14:461–70.
37. Zelenay S, Van Der Veen AG, Boettcher JP, et al. Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity. Cell 2014;162:1257–70.
38. Gresser I, Belardelli F. Endogenous type I interferons as a defense against tumors. Cytokine Growth Factor Rev 2002;13:111–8.
39. Keating SE, Baran M, Bowie AG. Cytosolic DNA sensors regulating type I interferon induction. Trends Immunol 2011;32:574–81.
40. Woo S-R, Fuertes MB, Corrales L, et al. The STING pathway mediates innate immune sensing of immunogenic tumors. Immunity 2014;41:830–42.
41. Deng L, Liang H, Xu M, et al. STING-dependent cytosolic DNA sensing promotes radiation-induced Type I interferon-dependent antitumor immunity in immunogenic tumors. Immunity 2014;41:843–52.
42. Lande R, Gregorio J, Facchinetti V, et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature 2007;449:564–9.
43. Fuertes MB, Woo S-R, Burnett B, et al. Type I interferon response and innate immune sensing of cancer. Trends Immunol 2013;34:67–73.
44. Darji A, Guzma CA, Gerstel B, et al. Oral somatic transgene vaccination using attenuated S. typhimurium 1997;91:765–75.
45. Saccheri F, Pozzi C, Avogadri F, et al. Bacteria-induced gap junctions in tumors favor antigen cross-presentation and antitumor immunity. Sci Transl Med 2010;2:44ra57
46. Gatti G, Nuñez NG, Nocera DA, et al. Direct effect of dsRNA mimetics on cancer cells induces endogenous IFN-β production capable of improving dendritic cell function. Eur J Immunol 2013;43:1849–61.
47. Ablasser A, Schmid-Burgk JL, Hemmerling I, et al. Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP. Nature 2013;503:530–4.
48. Schoggins JW, MacDuff DA, Imanaka N, et al. Pan-viral specificity of IFN-induced genes reveals new roles for cGAS in innate immunity. Nature 2014;505:691–5.
49. Sgorbissa A, Tomasella A, Potu H, et al. Type I IFNs signaling and apoptosis resistance in glioblastoma cells. Apoptosis 2011;16:1229–44.
50. Culig Z. Suppressors of cytokine signalling-3 and -1 in human carcinogenesis. Front Biosci (Schol Ed) 2013;5:277–83.